In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of patients...
These outstanding growth stocks are worth buying on the dip.
Now may be a good time for dividend investors to consider loading up on this stock.
There are very good reasons that stocks generally gain in value after a company receives %OrphanDrug designation (ODD). A study published in Orphanet Journal of Rare Diseases showed that the average stock...
If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. Positive Opinion...
One of these high-yield pharma stocks stands out as a better buy right now.
These two high-yield dividend stocks are attractive buys right now.
The company's collaboration agreement with Sanofi could soon pay off.
Takeda ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) resubmission for the investigational...
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.